STOCK TITAN

Sierra Oncology to Present at HC Wainwright BioConnect Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Sierra Oncology, Inc. (NASDAQ: SRRA) has announced its participation in the virtual 2022 HC Wainwright BioConnect Conference from January 10-13, 2022. CEO Stephen Dilly will present an overview of the company, available on demand starting at 7:00 am ET on January 10. A replay will be accessible for 90 days via the Investors section of Sierra's website. Sierra focuses on delivering targeted therapies for rare cancers, leveraging scientific expertise to transform cancer treatment paradigms.

Positive
  • None.
Negative
  • None.

SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 7:00 am ET on Monday, January 10 to conference attendees.

A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab. The replay will be available for approximately 90 days following the presentation.

About Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.

For more information, visit www.SierraOncology.com.

Investor Contact



DeDe Sheel

415.732.9828

dsheel@sierraoncology.com



Media Contact



Lauren Musto

615.351.7777

lmusto@sierraoncology.com

Source: Sierra Oncology, Inc.

FAQ

When is Sierra Oncology participating in the HC Wainwright BioConnect Conference?

Sierra Oncology will participate in the HC Wainwright BioConnect Conference from January 10-13, 2022.

What time will Sierra Oncology's presentation be available?

The presentation by Sierra Oncology will be available on demand starting at 7:00 am ET on January 10, 2022.

How can I access the replay of Sierra Oncology's presentation?

The replay of Sierra Oncology's presentation will be available for approximately 90 days in the Investors section of their corporate website.

What is the focus of Sierra Oncology as a company?

Sierra Oncology is dedicated to delivering targeted therapies for rare forms of cancer, aiming to transform the cancer treatment paradigm.

Who is the CEO of Sierra Oncology?

Stephen Dilly is the President and CEO of Sierra Oncology.

SRRA

NASDAQ:SRRA

SRRA Rankings

SRRA Latest News

SRRA Stock Data

1.34B
20.06M
8.5%
76.95%
2.34%
Biotechnology
Healthcare
Link
United States
San Mateo